Terlipressin is under clinical development by Ferring International Center and currently in Phase III for Unspecified Respiratory Disorders. According to GlobalData, Phase III drugs for Unspecified Respiratory Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Terlipressin LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Terlipressin overview
Terlipressin (Glypressin/Remestyp) is a vasopressin analogue acts as vasoconstrictor agent. It is formulated as injectable powder for solution and solution for intravenous route of administration. Glypressin is indicated for treatment of bleeding oesophageal varices, gastrointestinal bleeding and hepatorenal syndrome type 1.
It is also under development for the treatment of mild to severe hemoptysis. It was also under development for the treatment of bleeding esophageal varices in the US.
Ferring International Center overview
Ferring International Center (Ferring), a subsidiary of Ferring Holding SA, is a research-driven, specialty biopharmaceutical company. Its primary activities include research and development in reproductive medicine, women’s health, gastroenterology and urology. Ferring’s product portfolio includes treatments for reproductive medicine and maternal health, gastroenterology and microbiome, urology and uro-oncology, endocrinology and orthopedics. Ferring’s products are used by patients seeking treatments in the areas of reproductive health, gastroenterology, and urology, among others. The company has a global presence with manufacturing sites and R&D centers in countries such as China, Denmark, Brazil, Israel, Japan, India, the UK, and the US. Ferring Pharmaceuticals is headquartered in Saint-Prex, Switzerland.
For a complete picture of Terlipressin’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
